Oncology

Latest News

Microscopic view of non small cell lung cancer cells. Image Credit: © Keopaserth - stock.adobe.com

From Amivantamab to Next-Generation Therapies: The Evolving Bispecific Antibody Landscape in NSCLC

By Alana Hippensteele, MA

September 6th 2025

Bispecific antibodies are emerging as a transformative class in advanced non–small cell lung cancer (NSCLC), with agents such as amivantamab and zenocutuzumab already demonstrating clinical benefit and a broad pipeline of investigational therapies showing promise in overcoming resistance.

Lung cancer. Image Credit: © Dr Microbe - stock.adobe.com

Comparing Global Standards in Lung Cancer: NCCN, ESMO, and CHEST Guidelines

By Alana Hippensteele, MA

September 6th 2025

Most of the patients who experienced superior outcomes with atezolizumab and chemotherapy had higher levels of NOTCH1 expression. | Image credit: Pixel-Shot - stock.adobe.com

NOTCH1 Levels Impact Immune Response in SCLC

By Jared Kaltwasser

September 2nd 2025

The findings can help guide ongoing and future clinical trials to help solve remaining challenges in LS-SCLC. | Image credit: Jennifer - stock.adobe

Neoadjuvant Immunotherapy Plus Chemotherapy Shows Promise in LS-SCLC

By Jared Kaltwasser

August 31st 2025

PD-1 blockade has previously shown success in a first-line setting in ES-SCLC, and nab-paclitaxel is albumin-bound and solvent-free, which the investigators explained may minimize the toxicity associated with paclitaxel therapy. | Image credit: didesign - stock.adobe.com

Camrelizumab Plus Carboplatin, Nab-Paclitaxel Shows Efficacy in ES-SCLC

By Jared Kaltwasser

August 29th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

Continuing Medical Education

September 7th 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology

September 7th 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

More News

August 25th 2014

NIH's ALCHEMIST Trial Launched

August 22nd 2014

ASCO's Peter Yu, MD, and Priority Health's Burton VanderLaan, MD, to Give Keynotes at AJMCLive Event

Bringing stakeholders together is the mission of AJMCLive, the meeting series of The American Journal of Managed Care. It's reflected in the two keynote speakers for Patient-Centered Oncology Care on Nov. 14: a leader of physicians, Peter Yu, MD, the current president of ASCO; and a leader among payers, Burton VanderLaan, MD, FACP, medical director of Priority Health.

August 22nd 2014

AJMC Panel: Advances in Multiple Myeloma Therapy Extend Survival for Patients, Raising Cost Concerns

Mary Caffrey Nicole Beagin

August 22nd 2014

Study Points to Lack of Awareness on the BRCA-Ovarian Cancer Relation

75 percent of those at high risk for BRCA mutations have no idea they may have increased chance of ovarian cancer, drawing attention to the importance of genetic counseling.

August 22nd 2014

Beyond the Numbers, Kentucky's Beshear Brings Healthcare Success Stories to State Fair

Mary K. Caffrey

In the twilight of his term of office, Kentucky Gov. Steve Beshear is savoring the political fruits from a leap of faith made 15 months ago, when he spurned his Legislature and opted to expand Medicaid, citing a unique provision in Kentucky regulations. A year after the CMS visit, Beshear and his team are the subject of glowing reports, which describe how a commonwealth with a history of getting things wrong in healthcare has done just about everything right in Obamacare.

August 22nd 2014

3D Printer Generates BiodegradableTargeted Drug Delivery System

An innovative method for using affordable, consumer-grade 3D printers and materials has been developed to fabricate custom medical implants that can contain antibacterial and chemotherapeutic compounds for targeted drug delivery.

August 21st 2014

Illumina To Collaborate With Leading Pharma on a Multigene Diagnostic Panel

The panel, based on next-generation sequencing, will help select the target population - to deliver precision medicine and improve outcomes.

August 21st 2014

AJMC Panel Asks: Does it Pay to Use Pathways?

Nicole Beagin Mary Caffrey

Panel Discussion led by Seema Sonnad,PhD, that saw participation from ASCO's president Peter Paul Yu, MD; Jennifer Malin, MD, PhD, from WellPoint; Chadi Nabhan, MD, FACP, from the University of Chicago; and I.W. Tischler, MD, from Cigna.

August 21st 2014

Faster MRI Technique Comparable to the Conventional Screen

August 21st 2014

Achieving Value in Cancer Care-the Case of Low- and Middle-Income Countries

Ajay Aggarwal, MD Richard Sullivan, MD, PhD

August 21st 2014

The Global Perspective on Value in Cancer Care

Based on presentations by Elisabeth De Vries, MD, PhD Richard Sullivan, MD, PhD Lowell E. Schnipper, MD

August 21st 2014

Overdiagnosis and Overtreatment: The Cancer Paradigm

Based on presentations by Barbara L. Smith, MD, PhD Rina S. Punglia, MD, MPH Laura Esserman, MD, MBA,

August 21st 2014

In Conversation With ASCO President Peter Paul Yu

August 21st 2014

Clinical Pathway Adherence and Barriers to Coverage

August 20th 2014

NICE Turns Around to Support the Use of Celgene's Revlimid

The cost regulator for the NHS in England and Wales has said that Celgene's Revlimid should be an option for treating patients with a particular form of myelodysplastic syndromes.

ASCO President Peter P. Yu on Attending AJMC's Patient-Centered Oncology Care Meeting

August 20th 2014

ASCO President Peter P. Yu on Attending AJMC's Patient-Centered Oncology Care Meeting

Peter Paul Yu, MD, FASCO, who this summer became president of the American Society of Clinical Oncology, shared how the group is leading the discussion of what constitutes value in cancer care, as well as the need to engage all stakeholders in this critical topic.

August 20th 2014

Cancer Care in the United States: The Path Ahead

Surabhi Dangi-Garimella, PhD

August 20th 2014

The EGF Receptor (EGFR) Continues to Be a Promising Target in NSCLC

Based on presentations by Pasi A. Janne, MD, PhD Lecia V. Sequist, MD, MPH Gideon Michael Blumenthal, MD Lawrence H. Schwartz, MD

August 20th 2014

BMS and Celgene Announce Collaboration on An Immuno-Chemo Combination Regimen

Combining nab-paclitaxel with nivolumab is expected to have a synergistic effect in the various tumor types to be targeted, while providing Celgene access to the immunooncology race.

August 19th 2014

NIH Initiates ALCHEMIST Trials: Targeted Treatment in Early-Stage Lung Cancer

The trials will evaluate the efficacy of erlotinib or crizotinib in preventing lung cancer recurrence, as well as survival, in patients carrying mutations in either EGFR or ALK, who are clinically free of the disease.

August 19th 2014

Raising Awareness for Treating Adult Survivors of Childhood Cancers

Guidelines, such as those developed by the Children's Oncology Group, can prove a useful resource to monitor and/or treat adults who have previously been treated for a pediatric cancer.

August 19th 2014

Studies Point to Unnecessary Testing in Cancer, Particularly in the Older Population

The two studies, published in the August issue of JAMA Internal Medicine, examine the pros and cons of the current cancer screening methodologies.

August 18th 2014

Editorial: Can Gene Signatures Tell Us All?

The writer asks: is more information better, even if we don't understand what it means?

August 18th 2014

BRCA2 Mutation: Poor Prognosis in Prostate Cancer

The study, published in the British Journal of Cancer, observed poor survival at the end of the follow-up period in men carrying the mutation, compared to non-carriers.

August 18th 2014

Model Evaluates Efficient Use of the PSA Test

The analysis recommends conducting the PSA test in those less than 70 years of age, to avoid overdiagnosis while reducing death by at least 50%.

August 17th 2014

American Cancer Society Releases Guide for Prostate Cancer Survivor Management

August 16th 2014

Two Leading Cancer Organizations, ASCO and AACR, Take a Stand on E-Cigarettes

ASCO and AACR want to see stricter regulation of the products, touching various aspects such as flavors, child-proofing, refills etc.

August 15th 2014

Medicare Proposes Covering Newly Approved Cologuard Test for CRC Detection

The final decision on the proposal will be made only after a 30-day comment period.

August 15th 2014

"Value" Decision by NICE Met With Disapproval

Both, the scientific community and a charitable organization, Prostate Cancer UK, have criticized the drug approval body for not offering abiraterone to sufferers until after chemotherapy.

August 14th 2014

Fifteen-Year Study Identifies BMI as a Risk Factor for Ten Cancers

The study, published in Lancet, reaffirms that being obese and overweight can be a major health burden and can lead to various other diseases.

...

157 158 159 160 161 162 163 164 165

...

259 Prospect Plains Rd, Bldg H,
Monroe, NJ 08831

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions